• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권4호
• /
• pp.231-234
• /
• 2018

Peptic ulcer bleeding (PUB) is the most common cause of non-variceal upper gastrointestinal bleeding, and its frequency has been declining over the past decades. However, mortality from PUB persists, and it is still a serious challenge in clinical practice. Although endoscopic intervention is the basic treatment modality for PUB, pharmacological therapy is an important adjunct. The emergence of proton pump inhibitors (PPIs) enables maintenance of intragastric pH >6, which greatly helps in the treatment of PUB. Continuous intravenous infusion of high-dose PPI reduces the re-bleeding rate, thereby helping avoid additional surgery in patients with high-risk stigmata. Moreover, administration of PPIs prior to endoscopy may reduce the need for additional endoscopic intervention. Recently introduced gastric acid suppressants, such as potassium-competitive acid blockers, have shown promising results in further treatment of PUB.

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권4호
• /
• pp.235-241
• /
• 2018

Peptic ulcer bleeding is a common complication of peptic ulcer disease and the most common cause of upper gastrointestinal bleeding. Despite advances in drug usage and endoscopic modalities, no significant improvement is observed in the mortality rate of bleeding ulcers. The purpose of this review is to discuss various endoscopic hemostatic methods to treat peptic ulcer bleeding. Endoscopic hemostatic techniques can be classified into injection, mechanical, electrocoagulation, hemostatic powder, and endoscopic Doppler-guided hemostatic therapies (the last mentioned being a newly developed technique). Endoscopic hemostasis can be performed as mono or combination therapy using the aforementioned methods. Endoscopic hemostasis is the most important treatment for patients with peptic ulcer bleeding. Endoscopists should consider the treatment approach for peptic ulcer bleeding based on patient characteristics, the size and shape of the lesion, the endoscopist's expertise, and the resources and circumstances at each hospital. Follow-up studies are needed to evaluate the efficacy of newly developed hemostatic powder therapy and endoscopic Doppler-guided hemostasis.

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권3호
• /
• pp.209-212
• /
• 2018

We report a rare case of systemic amyloidosis with gastrointestinal and lymph node involvement. A 64-year-old woman was admitted to our hospital with dyspepsia and weight loss. Initial esophagogastroduodenoscopy (EGD) revealed nonspecific findings, and abdominal computed tomography showed necrotizing lymphadenopathy at the porta hepatis. Laparoscopic lymph node biopsy was performed under suspicion of tuberculous lymphadenopathy, but a definite diagnosis was not established. Follow-up EGD performed 6 months later revealed multiple telangiectasia-like lesions at the gastric body, and endoscopic biopsy revealed amyloid deposition. Through additional blood and urine protein electrophoresis, the patient was finally diagnosed with systemic amyloidosis associated with multiple myeloma. She was treated with dexamethasone, thalidomide, and bortezomib; however, she died 3 months after diagnosis because of pneumonia and multiple organ failure.

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권3호
• /
• pp.157-161
• /
• 2018

Liquid biopsy, the analysis of circulating biomarkers from peripheral blood, such as circulating tumor cells (CTCs) and circulating tumor DNA, and exosomes, offers a less invasive, new source of cancer-derived materials that may reflect the status of the disease better and thereby contribute to personalized treatment. Recent advances in microfluidics and molecular analysis technologies have resulted in greatly improved CTC enumeration and detection. In this article, we review commercially available technologies used to isolate CTCs from peripheral blood, including immunoaffinity and label-free, physical property-based isolation methods. Although enormous technological progress has been made, especially within the last decade, only a few CTC detection methods have been approved for routine clinical use. Here, we provide an overview of the current CTC isolation methods and examples of their potential application for early diagnosis, prognosis, treatment monitoring, and prediction of resistance to cancer therapy. Furthermore, the challenges that remain to be addressed before such tools are implemented for routine use in clinical settings are discussed.

• 생명과학회지
• /
• 제15권6호
• /
• pp.955-960
• /
• 2005

메트로니다졸은 인체 위장질환의 원인균인 헬리코박터 파일로리를 박별하기위해 처방하는 주요 약제이다 그러나 인체로부터 분리한 헬리코박터 파일로리 균주는 메트로니다졸에 내성을 가지는 경우가 일반적이며, 이러한 내성원인은 이 균주의 염색체 상에 존재하는 두 종류의 nitroreductase 유전자인 rdxA와frxA 유전자가 비활성화됨에 따라 유발된다. 본 연구에서는 헬리코박터 파일로리 균에서 rdxA 유전자에 변이를 도입하여 메트로니다졸에 내성을 가지는 균주를 구축하여, 메트로니다졸 내성이 균주에 미치는 생물학적 영향을 관찰하고자 하였다. In vitro상에서 메트로니다졸 내성균주는 대조균과 비교하여 exponential phase에서는 거의 차이 없이 증식하였으나 stationary phase에서는 빠르게 생육활성을 잃는 것을 관찰할 수 있었다. 또한 생쥐를 이용한 동물 실험에서 메트로니다졸 내성균주는 생쥐의 위장 내에서 서식하는 능력을 상실함을 알 수 있었다. 그러나 이러한 생육 활성을 회복시켜주는 compensate템 mutation을 가진 균주를 쉽게 얻을 수 있었으며 이 균주는 생쥐에 감염시키면 위장 내에서 서식하는 능력을 회복함을 알 수 있었다.

• 한국산학기술학회논문지
• /
• 제12권11호
• /
• pp.5094-5101
• /
• 2011

위암 완치수술을 받은 환자들의 재발수준과 재발에 미치는 영향을 파악하고자 2010년 9월부터 2011년 5월까지 한 대학병원에서 위암으로 진단받고 수술받은 환자 386명을 대상으로 조사하였다. 이들의 의무기록지와 병원암등록 자료에서 인구사회학적 특성, 생화학적 검사치, 임상병리학적 특성 등을 조사하였으며, 통계학적 검증으로 카이스퀘어 검정과 로지스틱 회귀분석을 실시하였다. 전체 조사대상자의 위암 재발률은 2.6%이었고, 성별 재발률은 남자에서 3.45%, 여자는 0.89%로 남자가 여자보다 약 4배정도 높았다. 단변량 로지스틱 회귀분석에서 재발이 발생할 위험은 림프전이가 있을수록 8.793배, 헬리코박터 파이로니균에 감염시 6.495배, 총콜레스테롤이 비정상일 때 14.333배 높았다. 다변량 로지스틱 회귀분석에서 림프전이와 헬리코박터 파이로니 감염이 재발에 중요한 요인으로 작용하였다. 결론적으로 위암의 재발에는 림프전이, 헬리코박터 파이로니 감염과 총콜레스테롤을 관리하고, CEA 및 CRP와 같은 생화학적 물질을 모니터링하여 재발을 조기에 발견하기 위한 노력이 함께 필요할 것으로 보인다.

• 과학과기술
• /
• 5호통권444호
• /
• pp.6-9
• /
• 2006

13만kg 넘는 우유 생난 '슈퍼 젖소' / 제주남부 남해해역 3차원 영상물 제작/식약청, 55개 원료 내년부터 금지/ 10여종의 암 진단 칩 상용화 전망/ '한국 별' 8,9호/ 헬리코박터 특정 균종이 위암 유발/ 암 치료용 '유도미사일' 제조기술 개발/ 바이러스 유전자 조작 배터리 용량 늘려/ 면역 질환 사료 신물질 개발/ 세포에 인위적인 신호 보내 질병 치료/ 호르몬 작용 타이머 발견/ 뇌졸중 치료 메커니즘 규명/ 굶주림 신호 보내는 메커니즘 밝혀

• 고려인삼학회:학술대회논문집
• /
• 고려인삼학회 2005년도 춘계 학술대회 및 총회
• /
• pp.8-11
• /
• 2005

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권4호
• /
• pp.258-263
• /
• 2018

Follicular lymphoma is the most common form of low-grade B cell lymphoma. Follicular lymphoma occurs predominantly at lymph node sites and rarely in the gastrointestinal tract. Rare gastrointestinal follicular lymphoma is most commonly found in the small intestine, especially in the duodenum, and appears as multiple granules. However, gastric follicular lymphoma mostly appears as a subepithelial tumor. We observed two primary gastric follicular lymphomas that resembled subepithelial tumors located in the body of the stomach. Endoscopic ultrasound revealed hypoechoic lesions located in the submucosa layer. Since endoscopic forceps biopsies were inconclusive, we performed endoscopic submucosal dissection, which resulted in a final pathologic diagnosis of follicular lymphoma. Because of the indolent nature of gastrointestinal follicular lymphoma, the "watch and wait" strategy can be applied in the early phase. The identification of endoscopic characteristics of gastric follicular lymphoma can be helpful for differential diagnosis and decision of treatment strategy. Therefore, we report two cases of primary gastrointestinal follicular lymphoma diagnosed following endoscopic submucosal dissection.

• 대한상부위장관⦁헬리코박터학회지
• /
• 제18권4호
• /
• pp.264-270
• /
• 2018

Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib mesylate. GISTs are resistant to conventional chemotherapy, and radiation therapy is not significantly beneficial for GISTs. With the development of imatinib mesylate, approximately 81.6% of patients with advanced and metastatic GIST exhibit an effect above the stabilization response, thereby increasing the survival time. However, imatinib mesylate alone is unlikely to cure metastatic GISTs. Even with a partial or stable response, imatinib mesylate may be used for a longer time period. However, resection of grossly visible lesions should be considered for patients with a stable response during surgical treatment. In this study, we present a case of GIST with liver metastasis after imatinib mesylate treatment, which was followed up without recurrence after partial resection.